当地时间9月4日,罗氏(Roche)公布了一项临床2期试验FENopta的开放标签扩展(OLE)研究48周新数据。结果表明,接受其在研BTK抑制剂Fenebrutinib(芬布替尼)治疗长达一年的复发性多发性硬化(RMS)患者中,高达96%患者没有发生疾病复发与进展。 罗氏表示将在...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis.https://www.biospace.com/press-releases/roches-fenebrut...
5月17日,罗氏(Roche)宣布,其口服 BTK 抑制剂 fenebrutinib 显著减少了患有复发型多发性硬化症 (MS) 的成年患者的脑损伤。 结果来自 FENopta II 期研究,该研究同时达到了主要和次要终点。 首席医疗官 Levi Garraway 表示:“我对这些临床数据感到鼓舞,”他补充说,“fenebrutinib 的作用机制可以抑制 B 细胞和小...
Schmucki, RolandRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandLi, CenxiaoHotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Calgary, CanadaDeGeer, Jonathan...
(Roche, 2021,2020). These randomized, double-blind, double-dummy, multicenter, parallel group studies will be examining ARR and time to onset of composite 12-week confirmed disability progression (cCDP12) as their primary outcome measures (Table 1). There is little currently known about the ...
周二,B. Riley的分析师写道,考虑到tolebrutinib相对于其他BTK抑制剂的“脑渗透效力”,赛诺菲的更新可能是其BTK抑制剂药物治疗复发性多发性硬化症的“终结”。罗氏(Roche)和诺华(Novartis)等公司目前正在进行后期试验。默克公司今年早些时候已经退出了竞争。
Genentech, a member of the Roche Group, announced positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis.
Hoffmann-La Roche, Inc. 100Clinical Results associated with Fenebrutinib Login to view more data 100Translational Medicine associated with Fenebrutinib Login to view more data 100Patents (Medical) associated with Fenebrutinib Login to view more data ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain ...
罗氏的fenebrutinib是一款口服、可逆、非共价的BTK抑制剂。临床前数据显示,fenebrutinib具有强效和高选择性,是目前处于MS III期临床试验中唯一一种可逆性抑制剂。Fenebrutinib对BTK的选择性是其他激酶的130倍,其高选择性和可逆性可限制分子的脱靶效应,可能有助于提高长期安全性,而长期安全性在需要长期持续用药的MS患...